Jaydess

Levonorgestrel, the active ingredient in Jaydess, is a progestin presented as a 13.5 mg intrauterine system for intrauterine use. It provides long‑acting hormonal contraception by releasing levonorgestrel directly within the uterine cavity, thereby preventing pregnancy in women of reproductive age.

GNH USA supplies Jaydess as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide. The company adheres to stringent quality standards and provides regulatory documentation for each shipment. Customers receive comprehensive technical support and can rely on timely delivery across multiple continents.

Levonorgestrel in Jaydess is a hormonal contraceptive used within the reproductive health pathway to prevent pregnancy.

- Contraception (prevention of pregnancy): provides highly effective, reversible birth control for women of child‑bearing age.

Jaydess may cause a range of adverse reactions, most of which are mild and transient.

Common Side Effects: - Irregular bleeding or spotting - Decreased menstrual bleeding or amenorrhea - Abdominal or pelvic discomfort - Breast tenderness

Serious or Rare Side Effects: - Uterine perforation during insertion - Device expulsion or displacement - Pelvic inflammatory disease or severe infection

Before insertion, clinicians should evaluate patient suitability and counsel on potential risks.

- Pregnancy screening: confirm the patient is not pregnant before placement - Contraindications: avoid in active pelvic infection, known uterine anomalies, or current pregnancy - Insertion by trained professional: ensure correct placement to minimise complications - Follow‑up visits: schedule post‑insertion checks to assess device position and patient response - Monitor for infection: advise patients to report fever, unusual discharge, or severe pain promptly - Store at ambient temperature: keep in original packaging, protect from moisture and direct heat

Levonorgestrel released from an intrauterine system has limited systemic exposure, yet some drug interactions may affect efficacy.

Major Interactions (Avoid): - Strong CYP3A4 enzyme inducers (e.g., phenytoin, carbamazepine, rifampicin): may reduce levonorgestrel levels and lower contraceptive effectiveness - Concurrent use of uterine‑acting agents that increase infection risk (e.g., intrauterine antibiotics): may heighten pelvic infection risk

Moderate Interactions (Monitor Closely): - Antifungal azoles (e.g., ketoconazole): may modestly increase systemic levonorgestrel exposure - HIV protease inhibitors: potential modest interaction, monitor for breakthrough bleeding - St. John's wort: may slightly reduce hormone levels, advise vigilance for reduced efficacy